Research Paper | Medicine Science | Iraq | Volume 6 Issue 11, November 2017
Incidence of Polyoma Virus Allograft Nephropathy among Iraqi Kidney Transplant Patients
Abstract: Background polyoma virus is a ubiquitous human virus with a peak incidence of primary infection in children 2 to 5 years of age and a seroprevalence rate of more than 60% to 90% among the adult population worldwide. Material and methodsAll recruited patients were considered from nephrology and transplant outpatients' clinic medical city (162cases, 97 males & 65 females). The patients with graft dysfunction were recorded on an already prepared data sheet for the type of induction therapy antithymocyte globulin (ATG or baxiliximab), type of immunosuppressant regimens, renal function test by estimation of Glomerular filtration rate (GFR by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, renal Doppler ultrasound, urine for decoy cell and renal graft biopsy for light microscopy and immunohistochmestry stain. ResultsThis cohort study enrolled Male patients were 97 while female patients were 65, the age ranges from 20 to 60 years 1. There was high incidence of PVAN among patients receiving antithymocyte globulin (ATG) (28.6%) as compare to baxiliximab group (3%). There were increasing incidence of BK virus nephropathy among patients taking (Calcineurin inhibitors (CNIs), + Steroid + Mycophenolate mofetil (MMF)), group (1) patients, the difference was statistically significant (p=0.012). There was increasing incidence of decoy cells in the urine of patients with PVAN (100%). ConclusionsThere was increasing incidence of PVAN among transplant recipient's patients. Histological feature of PVAN is reliable diagnostic tool and should be consider in every renal transplant patients.
Keywords: Graft Rejection, Kidney Transplantation, Polyomavirus
Edition: Volume 6 Issue 11, November 2017,
Pages: 1539 - 1544
Similar Articles with Keyword 'Graft'
Recurrent Atypical Hemolytic Uremic Syndrome Post-Renal Transplantation: Case Report Treated with Eculizumab
Abdullah Kashgary MD FRCPC